Cite
HARVARD Citation
Pu, X. et al. (n.d.). 226. Higher Doses of Adintrevimab, an Extended Half-Life Monoclonal Antibody, for the Treatment and Prevention of COVID-19: Preliminary Results from a Phase 1 Single Ascending-Dose Study. Open forum infectious diseases. p. . [Online].